Most Read Articles
Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

2 days ago
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.

Postresection intravesical gemcitabine cuts recurrence in nonmuscle-invasive urothelial cancer

21 Sep 2018

Administering intravesical gemcitabine immediately after tumour resection leads to a significant reduction in the long-term risk of recurrence in patients with suspected low-grade nonmuscle-invasive urothelial cancer, a study has shown.

A total of 406 patients (median age 66 years; 84.7 percent male) were randomized to receive intravesical instillation of gemcitabine (2 g in 100 mL of saline; n=201) or saline (100 mL; n=205) for 1 hour immediately following transurethral resection of bladder tumour (TURBT). None of the patients had any high-grade or >2 low-grade urothelial cancer episodes within 18 months before TURBT.

Evaluations were performed every 3 months with cystoscopy and cytology for 2 years and then semi-annually for 2 years. Patients were monitored for the occurrence of tumour recurrence, progression to muscle invasion, survival and toxic effects.

The primary outcome of recurrence of cancer occurred in 67 patients (35 percent) in the gemcitabine group and in 91 (47 percent) in the saline group within 4.0 years (hazard ratio [HR], 0.66; 95 percent CI, 0.48–0.90; p<0.001).

On the other hand, no significant between-group differences were observed in secondary endpoints. Specifically, five and 10 patients in the gemcitabine and saline groups had tumours that progressed to muscle invasion (p=0.22), while 17 and 25 patients, respectively, died of any cause (p=0.12).

No grade 4 or 5 adverse events (AEs) occurred, and AEs of grade ≤3 were comparable between the gemcitabine and saline groups.

Despite the presence of limitations, the present data support the use of intravesical gemcitabine in patients with suspected low-grade nonmuscle-invasive urothelial cancer, researchers said. However, additional research is needed to compare gemcitabine with other intravesical agents.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Christina Lau, 20 Apr 2020

Hippocampal avoidance during whole-brain radiotherapy (HA-WBRT), together with memantine, better preserves cognitive function vs WBRT plus memantine in patients with brain metastases, without compromising survival, a multi-institutional phase III trial has shown.

Natalia Reoutova, 20 May 2020

Cancer patients infected with coronavirus disease 2019 (COVID-19) appear to be at higher risk of severe outcomes, including death, but cancer type and treatment serve as better predictors, according to recent research presented at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting I.

At the time of writing, COVID-19 has spread to more than 200 countries and territories, affecting an estimated 4.5 million people and killing over 300,000. Cancer, on the other hand, is newly diagnosed in 18 million people and takes the lives of 10 million every year.

“We have invited physician scientists who are at the epicentre of the COVID-19 pandemic, taking care of patients with cancer. They gathered prospective information to understand the effects of COVID-19 on patients with cancer, are testing new treatments, and are making this knowledge available to the global research community, so we can all benefit from their experience,” said Professor Antoni Ribas from UCLA Medical Center, Los Angeles, California, US, chairperson of the COVID-19 and cancer plenary session of the meeting.

2 days ago
Case presentation: The patient is a 46-year-old Korean lady who first presented with aggravating pleuritic chest pain characterised by a stabbing pain in the chest when inhaling and exhaling. A diagnosis of non-small cell lung cancer (NSCLC) was made from computed tomography (CT)-guided needle aspiration biopsy, and the tumour was found to be epidermal growth factor receptor (EGFR) mutation-positive (exon 19 deletion). Chest imaging revealed the presence of left-sided pleural seeding nodules. The patient was treated with afatanib with partial response as best response. Ten months after starting treatment, the patient experienced disease progression.